Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

@article{Juif2016ClinicalPE,
  title={Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators},
  author={Pierre‐Eric Juif and Stephan Kraehenbuehl and Jasper Dingemanse},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2016},
  volume={12},
  pages={879 - 895}
}
ABSTRACT Introduction: Sphingosine-1-phosphate (S1P) receptor modulators, of which one has received marketing approval and several others are in clinical development, display promising potential in the treatment of a spectrum of autoimmune diseases. Areas covered: Administration of S1P1 receptor modulators leads to functional receptor antagonism triggering sustained inhibition of the egress of lymphocytes from lymphoid organs. First-dose administration is associated with transient… 
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies
TLDR
A comprehensive population PK model is built that accurately predicts the concentration–time data of ponesimod and indicates that the impact of the identified covariates on ponesIMod steady-state exposure is within 20 % of exposure, and thus within the margins of the IIV, with the exception of hepatic impairment.
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod
TLDR
The model developed here provides quantification of this effect for ponesimod and allows studying dosing regimens not clinically tested in silico, and indicates a better safety profile when using gradual uptitration.
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD
TLDR
Over the next few years physicians will have numerous options of small molecule drugs for the treatment of patients with IBD, potentially easier to use over biological agents due to pharmacokinetic features such as oral administration, short half-life, high volume of distribution, and lack of immunogenicity.
A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators.
TLDR
This review focuses on the various liquid chromatography with tandem mass spectrometry methods that have been used to quantify S1P1 modulators in various biological matrices and captures key information regarding sample processing options and chromatographic/detection conditions.
Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
TLDR
First-dose-related negative chronotropic effects of ponesimod were less pronounced when administered after initiation of cenerimod suggesting mitigation of this class-related liability.
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
TLDR
In conclusion, S1P modulators represent a novel and promising therapeutic strategy for immune-mediated diseases and concerns relating to S1PR modulators are leukopenia, anemia, transaminase elevation, macular edema, teratogenicity, pulmonary disorders, infections, and cardiovascular events.
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects
TLDR
A dose-dependent decrease in lymphocyte count was observed after initiation of cenerimod and reached a plateau (maximum change from baseline: −64%) after 20–23 days of treatment, and lymphocyte counts returned to baseline values at end-of-study examination.
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis
TLDR
A meta-analysis of controlled studies found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators, compared with a placebo or an active comparator.
First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
TLDR
The efficacy findings suggest that cenerimod has the potential to treat patients with SLE and further investigation in larger patient populations with longer treatment duration is warranted.
Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes
TLDR
These first models for ponesimod on the level of lymphocyte subsets offer a valuable tool for the analysis and interpretation of results from ponesIMod trials in autoimmune diseases.
...
...

References

SHOWING 1-10 OF 136 REFERENCES
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
TLDR
Three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compound potency on S 1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus brady Cardia and hypertension was consistent with affinity for S1 p1 relative to S1p3; and toxicity, brady cardia, and hypertension were absent in S1 P3-/- mice.
Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator
TLDR
Ponesimod (ACT-128800), a reversible, orally active, selective S1P1 receptor modulator, prevents the egress of lymphocytes from the lymph node into the systemic circulation and was instrumental for the selection of doses for subsequent studies that confirmed the effect plateau in total lymphocyte count.
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
TLDR
The results of this ascending single-dose study indicate an immunomodulator potential for ponesimod and a pharmacokinetic/pharmacodynamic profile consistent with once-a-day dosing.
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
TLDR
Functional antagonism of S1P1 by fingolimod results in a reduction in peripheral lymphocyte counts by inhibiting egress of lymphocytes, including potentially encephalitogenic T cells and their naïve progenitors that would otherwise be present within the circulation.
The role of sphingosine-1-phosphate receptor modulators in the prevention of transplant rejection and autoimmune diseases.
TLDR
Clinical trials have targeted S1P1 receptor modulators for autoimmune diseases, particularly for the potential treatment of multiple sclerosis and the prevention of transplant rejection, and the clinical experience with these compounds in MS and transplant rejection is summarized.
Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers
TLDR
Exercise induced robust increase in heart rate in subjects who had bradycardia following RD of GSK2018682 up to 6 mg, suggesting possible physiological methods of reducing the extent of S1P mediated bradycardsia and subsequent AV‐block.
Clinical Pharmacokinetics of Fingolimod
TLDR
Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing, and a predictable relationship between dose and systemic exposure.
Effects of Ethnicity and Sex on the Pharmacokinetics and Pharmacodynamics of the Selective Sphingosine-1-Phosphate Receptor 1 Modulator Ponesimod: A Clinical Study in Japanese and Caucasian Subjects
TLDR
This study showed that the PK and PD profile of ponesimod was similar in Japanese and Caucasian subjects, and no dose adjustment is deemed necessary for Japanese subjects compared to Caucasians.
Efficacy and immunomodulatory actions of ONO‐4641, a novel selective agonist for sphingosine 1‐phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
TLDR
In a rat experimental autoimmune encephalomyelitis (EAE) model, ONO‐4641 suppressed the onset of disease and inhibited lymphocyte infiltration into the spinal cord in a dose‐dependent manner at doses of 0·03 and 0·1 mg/kg.
Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects
TLDR
Ponesimod administered by both routes of administration was well tolerated and resulted in transient decreases in lymphocyte count and heart rate.
...
...